Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2] that targets IL-23.[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL23 |
| Clinical data | |
| Other names | MEDI2070 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6410H9830N1718O2016S50 |
| Molar mass | 144820.16 g·mol−1 |
This drug was developed by MedImmune.
References
edit- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- ^ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |